A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
Latest Information Update: 18 Apr 2025
At a glance
- Drugs Canakinumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Apr 2025 Planned End Date changed from 1 Jun 2025 to 1 Jan 2026.
- 15 Apr 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Aug 2025.
- 11 Aug 2023 New trial record